Watch the series now!
Icahn School of Medicine at Mount Sinai and Champions Oncology have initiated a study evaluating TumorGrafts' ability to predict treatment benefit in patients with triple-negative breast cancer. A side-by-side genomic analysis of patients' tumor and TumorGraft mouse avatars, before and after treatment, will also be conducted.
Low-dose dexamethasone with pomalidomide improved overall survival to 12.7 months, compared to 5.7 months with high-dose dexamethasone.
A bold new way to test cancer drugs started Monday in hundreds of hospitals around the United States.
A proteomic test can predict outcome with chemotherapy versus erlotinib in NSCLC patients.
The FDA has approved the diagnostic agent technetium 99m tilmanocept for the detection of the spread of head and neck cancers.
Cutting edge technology used to image young children with heart disease increases their risk of cancer.
Ventana Medical Systems, Inc. and MedImmune today announced they are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune's MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma. This includes the recently commenced MEDI4736 ATLANTIC trial that will enroll only patients who express PD-L1 as determined by the VENTANA assay.
New research suggests that a reduction in blood cholesterol might actually prove harmful in kidney cancer patients.
CYRAMZAâ„¢ (ramucirumab)did not meet its primary endpoint; overall survival favored the CYRAMZA arm but was not statistically significant, in patients with hepatocellular carcinoma, but meaningful improvements in key secondary endpoints of progression-free survival, overall response rate and time to progression were observed.
Pembrolizumab was safe and effective in patients with locally advanced or metastatic non—small cell lung cancer that strongly expressed PD-L1, according to study results presented at the ASCO Annual Meeting.
A study conducted at the Johns Hopkins University demonstrates improved detection of prostate cancer metastasis following the injection of 18F-DCFBC, which binds PSMA.
The agreement will help develop Rosetta's thyroid neoplasia assay.
Nearly 10% of women treated with herceptin were found to be susceptible to heart risks, which reversed once treatment was halted.
Patients who want to compare prices for prostate-cancer surgery may find it rough going: a study has found a 13-fold difference in prices quoted by 100 hospitals across the United States. Moreover, most provided little more than broad estimates, and only three gave a hard copy of the charges.
The continued advances in cancer treatment are improving patient survival, but the healthcare industry is bursting at its seams.
Taiho Pharmaceutical Co., parent company of Taiho Oncology, announced recently that its combination drug for refractory metastatic colorectal cancer met its primary endpoint in a phase 3 global RECOURSE trial.
New studies suggest that privately insured patients may receive better cancer care than Medicaid beneficiaries. Although a variety of factors impact patient access to cancer treatment, low-income patients were found to have greater difficulty with navigating health systems.
Weight loss surgery might have more value than simply helping morbidly obese people to shed unhealthy extra pounds. It reduces their risk of cancer to rates almost similar to those of people of normal weight.
A study conducted at the GW Cancer Institute identified issues faced by cancer care institutes in adopting patient-centered care programs.
Pristine nanotubes produced through a new process can be modified to carry drugs to tumors through gaps in blood-vessel walls that larger particles cannot fit through. The nanotubes may then target and infiltrate the cancerous cells' nuclei, where the drugs can be released through sonication.
Onartuzumab (MetMab)did not improve PFS when combined with erlotinib (Tarceva) in the METLung trial.
The American Society of Clinical Oncology's algorithm to help oncologists evaluate the clinical benefits, side effects and costs of a cancer drug or therapy will be fine-tuned over the summer and should be available for public comment by the fall, said Dr. Lowell Schnipper, chair of the society's Value in Cancer Care Task Force.
